The Motley Fool

The Oxford BioMedica share price surges on earnings

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background
Image source: Getty Images

The Oxford BioMedica (LSE:OXB) share price jumped by double-digits last week following its latest results. This recent momentum has pushed the stock’s 12-month performance to just over 90%. And as a long-time shareholder, I’ve been thoroughly enjoying the returns. But can it continue to climb from here? Let’s take a closer look.

The rising Oxford Biomedica share price

I’ve previously explored this business. But as a quick reminder, Oxford BioMedica is a young biotech firm that created a drug development platform called LentiVector. This has proven to be an essential solution for the more prominent drug developers like Novartis and AstraZeneca. The latter of which also struck a deal to hand its Covid-19 vaccine manufacturing responsibilities to this company.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

This manufacturing deal is largely responsible for the rapid rise in Oxford BioMedica’s share price – something I predicted back in November last year. And looking at the latest results, it’s clear to see why. Total revenue is up 139%, reaching £81.3m versus £34m over the same period in 2020.

£75.6m of the total revenue stream originated from its bioprocessing and commercial development division. This includes all the income generated through its partnerships with larger pharmaceutical companies, including AstraZeneca. The rest came from royalties and license fees. However, cash flow in this segment remains fairly volatile. And will likely stay that way until more drugs developed using LentiVector reach the market.

Overall, this explosive revenue growth has led to the company entering the black, with operating profits coming in at £19.7m versus a £5.8m loss last year. However, as impressive as this latest performance has been, there are some brewing concerns in my mind.

The risks that lie ahead

My original and ongoing investment thesis for this business surrounds its LentiVector platform. Clients pay an initial licence fee along with additional royalties should a developed drug eventually make it to the market. This makes it a long-term source of recurring income.

So, I’m disappointed to see that Sanofi is terminating its collaboration and licence agreement with Oxford BioMedica for its haemophilia treatment. The management team expects the impact on revenues over the next 24 months to be negligible. However, it begs the question of whether LentiVector is living up to expectations.

For now, its agreements with other pharmaceutical companies, including its recent collaboration with Bristol Myers Squibb, remain in place. Still, this is something I will be watching closely. Suppose its other partnerships start to crumble? In that case, the Oxford BioMedica share price could do the same.

The Oxford BioMedica share price has its risks

The bottom line

Overall, my opinions of this business is unchanged. These latest results are quite encouraging. And if the firm can continue to maintain its growth, I wouldn’t be surprised to see the Oxford BioMedica share price climb higher over the long term.

Having said that, I must admit, the stock is starting to look quite expensive. With a price-to-earnings ratio of over 70, the slightest hint of trouble, such as another lost partnership, would likely lead to a significant amount of volatility. With that in mind, I won’t be buying more shares today as I think there are cheaper opportunities to be found elsewhere.

Opportunities, such as...

The high-calibre small-cap stock flying under the City’s radar

Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…

You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.

And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.

Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.

But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before!

Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge!

Zaven Boyrazian owns shares of Oxford Biomedica. His mother is an employee of Bristol Myers Squibb involved in clinical trials. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.